Perrigo (PRGO) Competitors

Perrigo (NYSE:PRGO) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, community ranking, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Does the MarketBeat Community believe in PRGO or CORT?

Perrigo received 225 more outperform votes than Corcept Therapeutics when rated by MarketBeat users. However, 71.37% of users gave Corcept Therapeutics an outperform vote while only 66.35% of users gave Perrigo an outperform vote.

Company	Underperform	Outperform
Perrigo	Outperform Votes 771 66.35%	Underperform Votes 391 33.65%
Corcept Therapeutics	Outperform Votes 546 71.37%	Underperform Votes 219 28.63%

Does the media refer more to PRGO or CORT?

In the previous week, Corcept Therapeutics had 8 more articles in the media than Perrigo. MarketBeat recorded 21 mentions for Corcept Therapeutics and 13 mentions for Perrigo. Perrigo's average media sentiment score of 1.46 beat Corcept Therapeutics' score of 1.08 indicating that Perrigo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	11 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, PRGO or CORT?

Corcept Therapeutics has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.37B	0.78	-$12.70M	-$1.25	-20.03
Corcept Therapeutics	$675.04M	10.88	$106.14M	$1.24	56.12

Which has more risk and volatility, PRGO or CORT?

Perrigo has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500.

Do analysts rate PRGO or CORT?

Perrigo presently has a consensus target price of $33.00, indicating a potential upside of 31.78%. Corcept Therapeutics has a consensus target price of $143.25, indicating a potential upside of 105.85%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Corcept Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is PRGO or CORT more profitable?

Corcept Therapeutics has a net margin of 22.35% compared to Perrigo's net margin of -3.64%. Corcept Therapeutics' return on equity of 24.54% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-3.64%	7.38%	3.18%
Corcept Therapeutics	22.35%	24.54%	20.24%

Do insiders and institutionals hold more shares of PRGO or CORT?

95.9% of Perrigo shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 0.7% of Perrigo shares are held by insiders. Comparatively, 20.5% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Corcept Therapeutics beats Perrigo on 13 of the 18 factors compared between the two stocks.